Diagnosis of human immunodeficiency virus (HIV) infection with visceral leishmaniasis (VL) coinfection is challenging.Specific diagnosis of VL in HIV-coinfected patients was evaluated by molecular methods in desquamated buccal swab samples, demonstrating 86.3% sensitivity and 98.3% specificity in controls. This test holds significant potential for development as a noninvasive diagnostic tool for VL in HIV-coinfected patients.
Visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) coinfection has emerged as a serious disease prototype and is on the rise in India and Central and South America, posing a difficult challenge to VL subjugation efforts (1, 2). Since its first report in 1985, 35 countries have reported cases of this coinfection (3). In India, the prevalence of HIV-VL coinfection had been reported to be 2% to 5% in a limited number of studies (4). HIV infection increases the risk of developing VL by 100 to 2,320 times in areas of endemicity (5, 6) and greatly increases the probability of relapse cases. Interestingly, VL was also found to promote the clinical progression of HIV disease and AIDS-defining conditions (3). Parasitological diagnosis remains the gold standard in VL diagnosis due to its high specificity and sensitivity; molecular diagnosis is mainly based on PCR assays (7). In contrast, diagnosis of HIV-VL coinfection is very challenging as the clinical manifestations typical of VL are not always present and/or the patients might demonstrate several nonspecific clinical signs. As tissue aspiration for demonstration of the amastigote stage is potentially associated with dangerous risks, diagnosis in field settings is often based on signs, symptoms, and serology. Specifically, splenomegaly is less frequent in coinfected patients (8,9), and 42% to 68% of these patients have other associated opportunistic infections with analogous symptoms, further complicating the clinical diagnosis of VL (10). Presentation of amastigotes in peripheral blood smears of HIV-VL coinfected patients has a positivity rate of only 50% to 53% (11,12). Moreover, as HIV-VL patients present a low level of immune response, the validity and usefulness of a rapid immunochromatographic test (ICT) using recombinant antigen k-39 (rk39) would be doubtful even in cases of HIV coinfection (32). Commonly used laboratory diagnostic procedures for VL involve analyses of the cellular and chemical constituents of blood. However, researchers argue that easily collectable sputum samples or buccal swabs would be more practical for VL diagnosis, especially under field conditions (13,14). Interestingly, several studies have reported the presence of amastigotes in extraordinary locations, such as the spinal fluid, lungs, tonsils, larynx, digestive tract, rectum, etc., in HIV-VL patients (3,15,16,17). Therefore, in the current study, we investigated the potential of the buccal swab as the sample for noninvasive, safe molecular detection of VL in HIV-VL patients on the basis of the presence of leishmanial genomic DNA (gDNA).The study p...